nodes	percent_of_prediction	percent_of_DWPC	metapath
Canagliflozin—ABCC2—Ethinyl Estradiol—osteoporosis	0.112	0.18	CbGbCtD
Canagliflozin—ALB—Estropipate—osteoporosis	0.109	0.174	CbGbCtD
Canagliflozin—ABCC2—Conjugated Estrogens—osteoporosis	0.0825	0.132	CbGbCtD
Canagliflozin—ALB—Estradiol—osteoporosis	0.0451	0.0724	CbGbCtD
Canagliflozin—ABCB1—Ethinyl Estradiol—osteoporosis	0.0366	0.0587	CbGbCtD
Canagliflozin—CYP3A4—Estropipate—osteoporosis	0.0341	0.0546	CbGbCtD
Canagliflozin—CYP3A4—Calcitriol—osteoporosis	0.0341	0.0546	CbGbCtD
Canagliflozin—CYP3A4—Ergocalciferol—osteoporosis	0.0272	0.0437	CbGbCtD
Canagliflozin—ABCB1—Conjugated Estrogens—osteoporosis	0.0269	0.0431	CbGbCtD
Canagliflozin—ABCB1—Estradiol—osteoporosis	0.0236	0.0379	CbGbCtD
Canagliflozin—CYP3A4—Raloxifene—osteoporosis	0.0227	0.0364	CbGbCtD
Canagliflozin—CYP3A4—Ethinyl Estradiol—osteoporosis	0.0219	0.0352	CbGbCtD
Canagliflozin—CYP3A4—Cholecalciferol—osteoporosis	0.0175	0.0281	CbGbCtD
Canagliflozin—CYP3A4—Conjugated Estrogens—osteoporosis	0.0161	0.0258	CbGbCtD
Canagliflozin—CYP3A4—Estradiol—osteoporosis	0.0141	0.0227	CbGbCtD
Canagliflozin—Urethral disorder—Ethinyl Estradiol—osteoporosis	0.000547	0.00191	CcSEcCtD
Canagliflozin—Asthenia—Ergocalciferol—osteoporosis	0.000546	0.00191	CcSEcCtD
Canagliflozin—Pollakiuria—Zoledronate—osteoporosis	0.000545	0.00191	CcSEcCtD
Canagliflozin—Angioedema—Alendronate—osteoporosis	0.00054	0.00189	CcSEcCtD
Canagliflozin—Urinary tract disorder—Risedronate—osteoporosis	0.000538	0.00188	CcSEcCtD
Canagliflozin—Urethral disorder—Risedronate—osteoporosis	0.000534	0.00187	CcSEcCtD
Canagliflozin—Angioedema—Ibandronate—osteoporosis	0.000525	0.00184	CcSEcCtD
Canagliflozin—Syncope—Raloxifene—osteoporosis	0.000521	0.00182	CcSEcCtD
Canagliflozin—Urinary tract infection—Zoledronate—osteoporosis	0.000512	0.00179	CcSEcCtD
Canagliflozin—Nausea—Calcium Acetate—osteoporosis	0.000512	0.00179	CcSEcCtD
Canagliflozin—Urinary tract disorder—Pamidronate—osteoporosis	0.000511	0.00179	CcSEcCtD
Canagliflozin—Loss of consciousness—Raloxifene—osteoporosis	0.00051	0.00178	CcSEcCtD
Canagliflozin—Urethral disorder—Pamidronate—osteoporosis	0.000507	0.00177	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Estropipate—osteoporosis	0.000507	0.00177	CcSEcCtD
Canagliflozin—Angiopathy—Ethinyl Estradiol—osteoporosis	0.000506	0.00177	CcSEcCtD
Canagliflozin—Angiopathy—Risedronate—osteoporosis	0.000494	0.00173	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Raloxifene—osteoporosis	0.000491	0.00172	CcSEcCtD
Canagliflozin—Convulsion—Calcitriol—osteoporosis	0.000488	0.0017	CcSEcCtD
Canagliflozin—Infection—Estropipate—osteoporosis	0.000486	0.0017	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Ibandronate—osteoporosis	0.000486	0.0017	CcSEcCtD
Canagliflozin—Malnutrition—Ethinyl Estradiol—osteoporosis	0.000486	0.0017	CcSEcCtD
Canagliflozin—Constipation—Etidronic acid—osteoporosis	0.000484	0.00169	CcSEcCtD
Canagliflozin—Nervous system disorder—Estropipate—osteoporosis	0.00048	0.00168	CcSEcCtD
Canagliflozin—Infection—Alendronate—osteoporosis	0.000479	0.00167	CcSEcCtD
Canagliflozin—Dry mouth—Ibandronate—osteoporosis	0.000479	0.00167	CcSEcCtD
Canagliflozin—Breast disorder—Estradiol—osteoporosis	0.000476	0.00166	CcSEcCtD
Canagliflozin—Skin disorder—Estropipate—osteoporosis	0.000475	0.00166	CcSEcCtD
Canagliflozin—Malnutrition—Risedronate—osteoporosis	0.000474	0.00166	CcSEcCtD
Canagliflozin—Infection—Raloxifene—osteoporosis	0.000471	0.00165	CcSEcCtD
Canagliflozin—Angiopathy—Pamidronate—osteoporosis	0.000469	0.00164	CcSEcCtD
Canagliflozin—Dry mouth—Calcitriol—osteoporosis	0.000469	0.00164	CcSEcCtD
Canagliflozin—Urinary tract disorder—Zoledronate—osteoporosis	0.000467	0.00163	CcSEcCtD
Canagliflozin—Shock—Raloxifene—osteoporosis	0.000466	0.00163	CcSEcCtD
Canagliflozin—Infection—Ibandronate—osteoporosis	0.000466	0.00163	CcSEcCtD
Canagliflozin—Nervous system disorder—Raloxifene—osteoporosis	0.000465	0.00162	CcSEcCtD
Canagliflozin—Urethral disorder—Zoledronate—osteoporosis	0.000463	0.00162	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Etidronic acid—osteoporosis	0.000463	0.00162	CcSEcCtD
Canagliflozin—Shock—Ibandronate—osteoporosis	0.000462	0.00161	CcSEcCtD
Canagliflozin—Skin disorder—Raloxifene—osteoporosis	0.00046	0.00161	CcSEcCtD
Canagliflozin—Nervous system disorder—Ibandronate—osteoporosis	0.00046	0.00161	CcSEcCtD
Canagliflozin—Skin disorder—Ibandronate—osteoporosis	0.000456	0.00159	CcSEcCtD
Canagliflozin—Nausea—Ergocalciferol—osteoporosis	0.000452	0.00158	CcSEcCtD
Canagliflozin—Malnutrition—Pamidronate—osteoporosis	0.00045	0.00157	CcSEcCtD
Canagliflozin—Erythema—Pamidronate—osteoporosis	0.00045	0.00157	CcSEcCtD
Canagliflozin—Urticaria—Etidronic acid—osteoporosis	0.000449	0.00157	CcSEcCtD
Canagliflozin—Abdominal pain—Etidronic acid—osteoporosis	0.000447	0.00156	CcSEcCtD
Canagliflozin—Skin disorder—Calcitriol—osteoporosis	0.000446	0.00156	CcSEcCtD
Canagliflozin—Pancreatitis—Estradiol—osteoporosis	0.000446	0.00156	CcSEcCtD
Canagliflozin—Angioedema—Ethinyl Estradiol—osteoporosis	0.000444	0.00155	CcSEcCtD
Canagliflozin—Angioedema—Risedronate—osteoporosis	0.000433	0.00151	CcSEcCtD
Canagliflozin—Angiopathy—Zoledronate—osteoporosis	0.000429	0.0015	CcSEcCtD
Canagliflozin—Syncope—Risedronate—osteoporosis	0.000425	0.00149	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Estropipate—osteoporosis	0.000422	0.00148	CcSEcCtD
Canagliflozin—Fatigue—Estropipate—osteoporosis	0.000422	0.00147	CcSEcCtD
Canagliflozin—Pollakiuria—Estradiol—osteoporosis	0.00042	0.00147	CcSEcCtD
Canagliflozin—Constipation—Estropipate—osteoporosis	0.000418	0.00146	CcSEcCtD
Canagliflozin—Hypersensitivity—Etidronic acid—osteoporosis	0.000417	0.00146	CcSEcCtD
Canagliflozin—Loss of consciousness—Risedronate—osteoporosis	0.000416	0.00146	CcSEcCtD
Canagliflozin—Photosensitivity reaction—Estradiol—osteoporosis	0.000415	0.00145	CcSEcCtD
Canagliflozin—Angiopathy—Conjugated Estrogens—osteoporosis	0.000413	0.00144	CcSEcCtD
Canagliflozin—Constipation—Alendronate—osteoporosis	0.000412	0.00144	CcSEcCtD
Canagliflozin—Angioedema—Pamidronate—osteoporosis	0.000412	0.00144	CcSEcCtD
Canagliflozin—Malnutrition—Zoledronate—osteoporosis	0.000411	0.00144	CcSEcCtD
Canagliflozin—Erythema—Zoledronate—osteoporosis	0.000411	0.00144	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Ethinyl Estradiol—osteoporosis	0.000411	0.00144	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Raloxifene—osteoporosis	0.000409	0.00143	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Ibandronate—osteoporosis	0.000405	0.00142	CcSEcCtD
Canagliflozin—Fatigue—Ibandronate—osteoporosis	0.000405	0.00141	CcSEcCtD
Canagliflozin—Syncope—Pamidronate—osteoporosis	0.000404	0.00141	CcSEcCtD
Canagliflozin—Constipation—Ibandronate—osteoporosis	0.000401	0.0014	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Risedronate—osteoporosis	0.000401	0.0014	CcSEcCtD
Canagliflozin—Pruritus—Etidronic acid—osteoporosis	0.0004	0.0014	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Estropipate—osteoporosis	0.0004	0.0014	CcSEcCtD
Canagliflozin—Erythema—Conjugated Estrogens—osteoporosis	0.000396	0.00138	CcSEcCtD
Canagliflozin—Malnutrition—Conjugated Estrogens—osteoporosis	0.000396	0.00138	CcSEcCtD
Canagliflozin—Loss of consciousness—Pamidronate—osteoporosis	0.000396	0.00138	CcSEcCtD
Canagliflozin—Dry mouth—Risedronate—osteoporosis	0.000395	0.00138	CcSEcCtD
Canagliflozin—Urinary tract infection—Estradiol—osteoporosis	0.000394	0.00138	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Alendronate—osteoporosis	0.000394	0.00138	CcSEcCtD
Canagliflozin—Infection—Ethinyl Estradiol—osteoporosis	0.000394	0.00138	CcSEcCtD
Canagliflozin—Constipation—Calcitriol—osteoporosis	0.000393	0.00137	CcSEcCtD
Canagliflozin—Convulsion—Pamidronate—osteoporosis	0.00039	0.00136	CcSEcCtD
Canagliflozin—Nervous system disorder—Ethinyl Estradiol—osteoporosis	0.000389	0.00136	CcSEcCtD
Canagliflozin—Urticaria—Estropipate—osteoporosis	0.000389	0.00136	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Raloxifene—osteoporosis	0.000388	0.00135	CcSEcCtD
Canagliflozin—Abdominal pain—Estropipate—osteoporosis	0.000387	0.00135	CcSEcCtD
Canagliflozin—Skin disorder—Ethinyl Estradiol—osteoporosis	0.000385	0.00135	CcSEcCtD
Canagliflozin—Infection—Risedronate—osteoporosis	0.000384	0.00134	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Ibandronate—osteoporosis	0.000384	0.00134	CcSEcCtD
Canagliflozin—Urticaria—Alendronate—osteoporosis	0.000383	0.00134	CcSEcCtD
Canagliflozin—Abdominal pain—Alendronate—osteoporosis	0.000381	0.00133	CcSEcCtD
Canagliflozin—Shock—Risedronate—osteoporosis	0.00038	0.00133	CcSEcCtD
Canagliflozin—Nervous system disorder—Risedronate—osteoporosis	0.000379	0.00133	CcSEcCtD
Canagliflozin—Angioedema—Zoledronate—osteoporosis	0.000376	0.00131	CcSEcCtD
Canagliflozin—Skin disorder—Risedronate—osteoporosis	0.000376	0.00131	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Calcitriol—osteoporosis	0.000376	0.00131	CcSEcCtD
Canagliflozin—Abdominal pain—Raloxifene—osteoporosis	0.000375	0.00131	CcSEcCtD
Canagliflozin—Urticaria—Ibandronate—osteoporosis	0.000373	0.0013	CcSEcCtD
Canagliflozin—Abdominal pain—Ibandronate—osteoporosis	0.000371	0.0013	CcSEcCtD
Canagliflozin—Syncope—Zoledronate—osteoporosis	0.000369	0.00129	CcSEcCtD
Canagliflozin—Infection—Pamidronate—osteoporosis	0.000365	0.00128	CcSEcCtD
Canagliflozin—Urticaria—Calcitriol—osteoporosis	0.000365	0.00128	CcSEcCtD
Canagliflozin—Abdominal pain—Calcitriol—osteoporosis	0.000363	0.00127	CcSEcCtD
Canagliflozin—Angioedema—Conjugated Estrogens—osteoporosis	0.000362	0.00127	CcSEcCtD
Canagliflozin—Shock—Pamidronate—osteoporosis	0.000362	0.00126	CcSEcCtD
Canagliflozin—Loss of consciousness—Zoledronate—osteoporosis	0.000362	0.00126	CcSEcCtD
Canagliflozin—Hypersensitivity—Estropipate—osteoporosis	0.000361	0.00126	CcSEcCtD
Canagliflozin—Nervous system disorder—Pamidronate—osteoporosis	0.00036	0.00126	CcSEcCtD
Canagliflozin—Urinary tract disorder—Estradiol—osteoporosis	0.00036	0.00126	CcSEcCtD
Canagliflozin—Urethral disorder—Estradiol—osteoporosis	0.000357	0.00125	CcSEcCtD
Canagliflozin—Rash—Etidronic acid—osteoporosis	0.000357	0.00125	CcSEcCtD
Canagliflozin—Convulsion—Zoledronate—osteoporosis	0.000356	0.00125	CcSEcCtD
Canagliflozin—Dermatitis—Etidronic acid—osteoporosis	0.000356	0.00125	CcSEcCtD
Canagliflozin—Syncope—Conjugated Estrogens—osteoporosis	0.000355	0.00124	CcSEcCtD
Canagliflozin—Hypersensitivity—Alendronate—osteoporosis	0.000355	0.00124	CcSEcCtD
Canagliflozin—Asthenia—Estropipate—osteoporosis	0.000351	0.00123	CcSEcCtD
Canagliflozin—Loss of consciousness—Conjugated Estrogens—osteoporosis	0.000348	0.00122	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Zoledronate—osteoporosis	0.000348	0.00122	CcSEcCtD
Canagliflozin—Pruritus—Estropipate—osteoporosis	0.000346	0.00121	CcSEcCtD
Canagliflozin—Asthenia—Alendronate—osteoporosis	0.000346	0.00121	CcSEcCtD
Canagliflozin—Hypersensitivity—Ibandronate—osteoporosis	0.000346	0.00121	CcSEcCtD
Canagliflozin—Hypotension—Pamidronate—osteoporosis	0.000343	0.0012	CcSEcCtD
Canagliflozin—Convulsion—Conjugated Estrogens—osteoporosis	0.000343	0.0012	CcSEcCtD
Canagliflozin—Dry mouth—Zoledronate—osteoporosis	0.000343	0.0012	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Ethinyl Estradiol—osteoporosis	0.000342	0.0012	CcSEcCtD
Canagliflozin—Fatigue—Ethinyl Estradiol—osteoporosis	0.000342	0.0012	CcSEcCtD
Canagliflozin—Pruritus—Alendronate—osteoporosis	0.000341	0.00119	CcSEcCtD
Canagliflozin—Constipation—Ethinyl Estradiol—osteoporosis	0.000339	0.00119	CcSEcCtD
Canagliflozin—Hypersensitivity—Calcitriol—osteoporosis	0.000338	0.00118	CcSEcCtD
Canagliflozin—Asthenia—Ibandronate—osteoporosis	0.000337	0.00118	CcSEcCtD
Canagliflozin—Nausea—Etidronic acid—osteoporosis	0.000336	0.00117	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Conjugated Estrogens—osteoporosis	0.000335	0.00117	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Risedronate—osteoporosis	0.000334	0.00117	CcSEcCtD
Canagliflozin—Infection—Zoledronate—osteoporosis	0.000334	0.00117	CcSEcCtD
Canagliflozin—Fatigue—Risedronate—osteoporosis	0.000333	0.00117	CcSEcCtD
Canagliflozin—Pruritus—Ibandronate—osteoporosis	0.000332	0.00116	CcSEcCtD
Canagliflozin—Constipation—Risedronate—osteoporosis	0.000331	0.00116	CcSEcCtD
Canagliflozin—Angiopathy—Estradiol—osteoporosis	0.00033	0.00116	CcSEcCtD
Canagliflozin—Shock—Zoledronate—osteoporosis	0.00033	0.00115	CcSEcCtD
Canagliflozin—Asthenia—Calcitriol—osteoporosis	0.00033	0.00115	CcSEcCtD
Canagliflozin—Nervous system disorder—Zoledronate—osteoporosis	0.000329	0.00115	CcSEcCtD
Canagliflozin—Skin disorder—Zoledronate—osteoporosis	0.000326	0.00114	CcSEcCtD
Canagliflozin—Pruritus—Calcitriol—osteoporosis	0.000325	0.00114	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Ethinyl Estradiol—osteoporosis	0.000324	0.00113	CcSEcCtD
Canagliflozin—Dizziness—Estropipate—osteoporosis	0.000324	0.00113	CcSEcCtD
Canagliflozin—Infection—Conjugated Estrogens—osteoporosis	0.000321	0.00112	CcSEcCtD
Canagliflozin—Dizziness—Alendronate—osteoporosis	0.000319	0.00111	CcSEcCtD
Canagliflozin—Shock—Conjugated Estrogens—osteoporosis	0.000318	0.00111	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Pamidronate—osteoporosis	0.000317	0.00111	CcSEcCtD
Canagliflozin—Nervous system disorder—Conjugated Estrogens—osteoporosis	0.000317	0.00111	CcSEcCtD
Canagliflozin—Malnutrition—Estradiol—osteoporosis	0.000317	0.00111	CcSEcCtD
Canagliflozin—Erythema—Estradiol—osteoporosis	0.000317	0.00111	CcSEcCtD
Canagliflozin—Fatigue—Pamidronate—osteoporosis	0.000317	0.00111	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Risedronate—osteoporosis	0.000316	0.00111	CcSEcCtD
Canagliflozin—Urticaria—Ethinyl Estradiol—osteoporosis	0.000315	0.0011	CcSEcCtD
Canagliflozin—Constipation—Pamidronate—osteoporosis	0.000314	0.0011	CcSEcCtD
Canagliflozin—Skin disorder—Conjugated Estrogens—osteoporosis	0.000314	0.0011	CcSEcCtD
Canagliflozin—Hypotension—Zoledronate—osteoporosis	0.000314	0.0011	CcSEcCtD
Canagliflozin—Abdominal pain—Ethinyl Estradiol—osteoporosis	0.000314	0.0011	CcSEcCtD
Canagliflozin—Dizziness—Raloxifene—osteoporosis	0.000313	0.0011	CcSEcCtD
Canagliflozin—Dizziness—Ibandronate—osteoporosis	0.00031	0.00108	CcSEcCtD
Canagliflozin—Rash—Estropipate—osteoporosis	0.000309	0.00108	CcSEcCtD
Canagliflozin—Dermatitis—Estropipate—osteoporosis	0.000308	0.00108	CcSEcCtD
Canagliflozin—Urticaria—Risedronate—osteoporosis	0.000307	0.00107	CcSEcCtD
Canagliflozin—Abdominal pain—Risedronate—osteoporosis	0.000306	0.00107	CcSEcCtD
Canagliflozin—Rash—Alendronate—osteoporosis	0.000304	0.00106	CcSEcCtD
Canagliflozin—Dermatitis—Alendronate—osteoporosis	0.000304	0.00106	CcSEcCtD
Canagliflozin—Hypotension—Conjugated Estrogens—osteoporosis	0.000302	0.00106	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Pamidronate—osteoporosis	0.000301	0.00105	CcSEcCtD
Canagliflozin—Rash—Raloxifene—osteoporosis	0.000299	0.00104	CcSEcCtD
Canagliflozin—Dermatitis—Raloxifene—osteoporosis	0.000299	0.00104	CcSEcCtD
Canagliflozin—Rash—Ibandronate—osteoporosis	0.000296	0.00103	CcSEcCtD
Canagliflozin—Dermatitis—Ibandronate—osteoporosis	0.000296	0.00103	CcSEcCtD
Canagliflozin—Hypersensitivity—Ethinyl Estradiol—osteoporosis	0.000292	0.00102	CcSEcCtD
Canagliflozin—Nausea—Estropipate—osteoporosis	0.000291	0.00102	CcSEcCtD
Canagliflozin—Abdominal pain—Pamidronate—osteoporosis	0.000291	0.00102	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Zoledronate—osteoporosis	0.00029	0.00101	CcSEcCtD
Canagliflozin—Angioedema—Estradiol—osteoporosis	0.00029	0.00101	CcSEcCtD
Canagliflozin—Rash—Calcitriol—osteoporosis	0.00029	0.00101	CcSEcCtD
Canagliflozin—Fatigue—Zoledronate—osteoporosis	0.000289	0.00101	CcSEcCtD
Canagliflozin—Dermatitis—Calcitriol—osteoporosis	0.000289	0.00101	CcSEcCtD
Canagliflozin—Constipation—Zoledronate—osteoporosis	0.000287	0.001	CcSEcCtD
Canagliflozin—Nausea—Alendronate—osteoporosis	0.000286	0.001	CcSEcCtD
Canagliflozin—Hypersensitivity—Risedronate—osteoporosis	0.000285	0.000996	CcSEcCtD
Canagliflozin—Asthenia—Ethinyl Estradiol—osteoporosis	0.000285	0.000995	CcSEcCtD
Canagliflozin—Syncope—Estradiol—osteoporosis	0.000284	0.000994	CcSEcCtD
Canagliflozin—Nausea—Raloxifene—osteoporosis	0.000282	0.000984	CcSEcCtD
Canagliflozin—Pruritus—Ethinyl Estradiol—osteoporosis	0.000281	0.000981	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Conjugated Estrogens—osteoporosis	0.000279	0.000976	CcSEcCtD
Canagliflozin—Fatigue—Conjugated Estrogens—osteoporosis	0.000279	0.000974	CcSEcCtD
Canagliflozin—Nausea—Ibandronate—osteoporosis	0.000279	0.000974	CcSEcCtD
Canagliflozin—Loss of consciousness—Estradiol—osteoporosis	0.000279	0.000974	CcSEcCtD
Canagliflozin—Asthenia—Risedronate—osteoporosis	0.000277	0.00097	CcSEcCtD
Canagliflozin—Constipation—Conjugated Estrogens—osteoporosis	0.000276	0.000967	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Zoledronate—osteoporosis	0.000275	0.00096	CcSEcCtD
Canagliflozin—Pruritus—Risedronate—osteoporosis	0.000274	0.000956	CcSEcCtD
Canagliflozin—Nausea—Calcitriol—osteoporosis	0.000273	0.000954	CcSEcCtD
Canagliflozin—Hypersensitivity—Pamidronate—osteoporosis	0.000271	0.000947	CcSEcCtD
Canagliflozin—Unspecified disorder of skin and subcutaneous tissue—Estradiol—osteoporosis	0.000268	0.000937	CcSEcCtD
Canagliflozin—Urticaria—Zoledronate—osteoporosis	0.000267	0.000932	CcSEcCtD
Canagliflozin—Abdominal pain—Zoledronate—osteoporosis	0.000265	0.000928	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Conjugated Estrogens—osteoporosis	0.000264	0.000924	CcSEcCtD
Canagliflozin—Dry mouth—Estradiol—osteoporosis	0.000264	0.000923	CcSEcCtD
Canagliflozin—Asthenia—Pamidronate—osteoporosis	0.000264	0.000922	CcSEcCtD
Canagliflozin—Dizziness—Ethinyl Estradiol—osteoporosis	0.000262	0.000917	CcSEcCtD
Canagliflozin—Pruritus—Pamidronate—osteoporosis	0.00026	0.000909	CcSEcCtD
Canagliflozin—Infection—Estradiol—osteoporosis	0.000257	0.000899	CcSEcCtD
Canagliflozin—Urticaria—Conjugated Estrogens—osteoporosis	0.000257	0.000898	CcSEcCtD
Canagliflozin—Dizziness—Risedronate—osteoporosis	0.000256	0.000894	CcSEcCtD
Canagliflozin—Abdominal pain—Conjugated Estrogens—osteoporosis	0.000256	0.000893	CcSEcCtD
Canagliflozin—Shock—Estradiol—osteoporosis	0.000255	0.00089	CcSEcCtD
Canagliflozin—Nervous system disorder—Estradiol—osteoporosis	0.000254	0.000887	CcSEcCtD
Canagliflozin—Skin disorder—Estradiol—osteoporosis	0.000251	0.000879	CcSEcCtD
Canagliflozin—Rash—Ethinyl Estradiol—osteoporosis	0.00025	0.000874	CcSEcCtD
Canagliflozin—Dermatitis—Ethinyl Estradiol—osteoporosis	0.00025	0.000873	CcSEcCtD
Canagliflozin—Hypersensitivity—Zoledronate—osteoporosis	0.000247	0.000865	CcSEcCtD
Canagliflozin—Rash—Risedronate—osteoporosis	0.000244	0.000852	CcSEcCtD
Canagliflozin—Dermatitis—Risedronate—osteoporosis	0.000244	0.000852	CcSEcCtD
Canagliflozin—Dizziness—Pamidronate—osteoporosis	0.000243	0.00085	CcSEcCtD
Canagliflozin—Asthenia—Zoledronate—osteoporosis	0.000241	0.000842	CcSEcCtD
Canagliflozin—Hypersensitivity—Conjugated Estrogens—osteoporosis	0.000238	0.000833	CcSEcCtD
Canagliflozin—Pruritus—Zoledronate—osteoporosis	0.000238	0.00083	CcSEcCtD
Canagliflozin—Nausea—Ethinyl Estradiol—osteoporosis	0.000236	0.000824	CcSEcCtD
Canagliflozin—Asthenia—Conjugated Estrogens—osteoporosis	0.000232	0.000811	CcSEcCtD
Canagliflozin—Rash—Pamidronate—osteoporosis	0.000232	0.00081	CcSEcCtD
Canagliflozin—Dermatitis—Pamidronate—osteoporosis	0.000232	0.000809	CcSEcCtD
Canagliflozin—Nausea—Risedronate—osteoporosis	0.00023	0.000803	CcSEcCtD
Canagliflozin—Pruritus—Conjugated Estrogens—osteoporosis	0.000229	0.0008	CcSEcCtD
Canagliflozin—Gastrointestinal disorder—Estradiol—osteoporosis	0.000223	0.000781	CcSEcCtD
Canagliflozin—Fatigue—Estradiol—osteoporosis	0.000223	0.00078	CcSEcCtD
Canagliflozin—Dizziness—Zoledronate—osteoporosis	0.000222	0.000776	CcSEcCtD
Canagliflozin—Constipation—Estradiol—osteoporosis	0.000221	0.000774	CcSEcCtD
Canagliflozin—Nausea—Pamidronate—osteoporosis	0.000218	0.000763	CcSEcCtD
Canagliflozin—Dizziness—Conjugated Estrogens—osteoporosis	0.000214	0.000747	CcSEcCtD
Canagliflozin—Rash—Zoledronate—osteoporosis	0.000212	0.00074	CcSEcCtD
Canagliflozin—Gastrointestinal pain—Estradiol—osteoporosis	0.000212	0.00074	CcSEcCtD
Canagliflozin—Dermatitis—Zoledronate—osteoporosis	0.000212	0.000739	CcSEcCtD
Canagliflozin—Urticaria—Estradiol—osteoporosis	0.000206	0.000719	CcSEcCtD
Canagliflozin—Abdominal pain—Estradiol—osteoporosis	0.000205	0.000715	CcSEcCtD
Canagliflozin—Rash—Conjugated Estrogens—osteoporosis	0.000204	0.000713	CcSEcCtD
Canagliflozin—Dermatitis—Conjugated Estrogens—osteoporosis	0.000204	0.000712	CcSEcCtD
Canagliflozin—Nausea—Zoledronate—osteoporosis	0.000199	0.000697	CcSEcCtD
Canagliflozin—Nausea—Conjugated Estrogens—osteoporosis	0.000192	0.000671	CcSEcCtD
Canagliflozin—Hypersensitivity—Estradiol—osteoporosis	0.000191	0.000666	CcSEcCtD
Canagliflozin—Asthenia—Estradiol—osteoporosis	0.000186	0.000649	CcSEcCtD
Canagliflozin—Pruritus—Estradiol—osteoporosis	0.000183	0.00064	CcSEcCtD
Canagliflozin—SLC5A2—Metabolism—P4HB—osteoporosis	0.000179	0.00199	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—P4HB—osteoporosis	0.000179	0.00199	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—SOD2—osteoporosis	0.000178	0.00197	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—GAPDH—osteoporosis	0.000176	0.00195	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—GAPDH—osteoporosis	0.000176	0.00195	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	0.000174	0.00192	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—IDH2—osteoporosis	0.000173	0.00192	CbGpPWpGaD
Canagliflozin—UGT1A9—NRF2 pathway—AGER—osteoporosis	0.000173	0.00192	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—PLEK—osteoporosis	0.000173	0.00191	CbGpPWpGaD
Canagliflozin—UGT1A9—Aryl Hydrocarbon Receptor Pathway—TNF—osteoporosis	0.000172	0.00191	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—RAP1A—osteoporosis	0.000172	0.0019	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—RAP1A—osteoporosis	0.000172	0.0019	CbGpPWpGaD
Canagliflozin—Dizziness—Estradiol—osteoporosis	0.000171	0.000598	CcSEcCtD
Canagliflozin—ALB—Folate Metabolism—GPX1—osteoporosis	0.00017	0.00188	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	0.000169	0.00188	CbGpPWpGaD
Canagliflozin—ABCC2—NRF2 pathway—AGER—osteoporosis	0.000169	0.00187	CbGpPWpGaD
Canagliflozin—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—osteoporosis	0.000167	0.00185	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—ENO1—osteoporosis	0.000166	0.00183	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—ENO1—osteoporosis	0.000166	0.00183	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PSMA5—osteoporosis	0.000163	0.00181	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PSMA2—osteoporosis	0.000163	0.00181	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—PSMA2—osteoporosis	0.000163	0.00181	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—PSMA5—osteoporosis	0.000163	0.00181	CbGpPWpGaD
Canagliflozin—Rash—Estradiol—osteoporosis	0.000163	0.00057	CcSEcCtD
Canagliflozin—Dermatitis—Estradiol—osteoporosis	0.000163	0.00057	CcSEcCtD
Canagliflozin—UGT2B4—Metabolism—CYP27A1—osteoporosis	0.000163	0.0018	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—ACP5—osteoporosis	0.000159	0.00176	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—MTHFR—osteoporosis	0.000157	0.00174	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—WDR1—osteoporosis	0.000155	0.00172	CbGpPWpGaD
Canagliflozin—Nausea—Estradiol—osteoporosis	0.000154	0.000537	CcSEcCtD
Canagliflozin—SLC5A1—Disease—CALCA—osteoporosis	0.000152	0.00168	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—CALCA—osteoporosis	0.000152	0.00168	CbGpPWpGaD
Canagliflozin—CYP3A4—Tryptophan metabolism—CYP19A1—osteoporosis	0.00015	0.00167	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—TLN1—osteoporosis	0.000149	0.00165	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—TPI1—osteoporosis	0.000147	0.00163	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—VCL—osteoporosis	0.000147	0.00163	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—ANXA2—osteoporosis	0.000144	0.00159	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—SOD2—osteoporosis	0.000142	0.00157	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—ENO1—osteoporosis	0.000139	0.00154	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—ENO1—osteoporosis	0.000139	0.00154	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—P4HB—osteoporosis	0.000139	0.00153	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—KL—osteoporosis	0.000138	0.00153	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—KL—osteoporosis	0.000138	0.00153	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PSMA2—osteoporosis	0.000137	0.00151	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PSMA5—osteoporosis	0.000137	0.00151	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—PSMA5—osteoporosis	0.000137	0.00151	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—PSMA2—osteoporosis	0.000137	0.00151	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—GAPDH—osteoporosis	0.000136	0.00151	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	0.000135	0.0015	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—GPX1—osteoporosis	0.000135	0.00149	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—RAP1A—osteoporosis	0.000132	0.00147	CbGpPWpGaD
Canagliflozin—ABCB1—HIF-1-alpha transcription factor network—LEP—osteoporosis	0.000128	0.00142	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—MTHFR—osteoporosis	0.000125	0.00138	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—FDPS—osteoporosis	0.000123	0.00137	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—RAP1A—osteoporosis	0.000123	0.00136	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—CAP1—osteoporosis	0.000123	0.00136	CbGpPWpGaD
Canagliflozin—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP19A1—osteoporosis	0.000122	0.00135	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—RAP1A—osteoporosis	0.000121	0.00134	CbGpPWpGaD
Canagliflozin—CYP3A4—Oxidation by Cytochrome P450—CYP19A1—osteoporosis	0.00012	0.00133	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—GPD2—osteoporosis	0.000117	0.0013	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	0.000115	0.00128	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—IL1B—osteoporosis	0.000114	0.00127	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—FGA—osteoporosis	0.000111	0.00123	CbGpPWpGaD
Canagliflozin—UGT1A9—Biological oxidations—POMC—osteoporosis	0.000111	0.00123	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—CYP19A1—osteoporosis	0.000111	0.00123	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—CYP19A1—osteoporosis	0.000111	0.00123	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—ADCY5—osteoporosis	0.000108	0.0012	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—ADCY5—osteoporosis	0.000108	0.0012	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—ENO1—osteoporosis	0.000107	0.00119	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PSMA2—osteoporosis	0.000106	0.00117	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—PSMA5—osteoporosis	0.000106	0.00117	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PKM—osteoporosis	0.000105	0.00116	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—FDPS—osteoporosis	0.000105	0.00116	CbGpPWpGaD
Canagliflozin—ALB—Platelet degranulation—IGF1—osteoporosis	0.000103	0.00115	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—FGB—osteoporosis	0.000101	0.00112	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—CYP27A1—osteoporosis	9.97e-05	0.0011	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GPD2—osteoporosis	9.96e-05	0.0011	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PGLS—osteoporosis	9.96e-05	0.0011	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—MTHFR—osteoporosis	9.95e-05	0.0011	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—MTHFR—osteoporosis	9.95e-05	0.0011	CbGpPWpGaD
Canagliflozin—CYP3A4—Phase 1 - Functionalization of compounds—CYP19A1—osteoporosis	9.86e-05	0.00109	CbGpPWpGaD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—IGF1—osteoporosis	9.86e-05	0.00109	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—CYP27A1—osteoporosis	9.83e-05	0.00109	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—MGLL—osteoporosis	9.74e-05	0.00108	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—IRS2—osteoporosis	9.47e-05	0.00105	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—IRS2—osteoporosis	9.47e-05	0.00105	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—IL1B—osteoporosis	9.31e-05	0.00103	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PNP—osteoporosis	9.11e-05	0.00101	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ATIC—osteoporosis	9.11e-05	0.00101	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—OXCT1—osteoporosis	9.1e-05	0.00101	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—ADCY5—osteoporosis	9.06e-05	0.001	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—ADCY5—osteoporosis	9.06e-05	0.001	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—GPX1—osteoporosis	9.03e-05	0.001	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—GPX1—osteoporosis	9.03e-05	0.001	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—ANXA2—osteoporosis	8.91e-05	0.000987	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—PLEK—osteoporosis	8.91e-05	0.000987	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—MGLL—osteoporosis	8.87e-05	0.000982	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—osteoporosis	8.61e-05	0.000953	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—CYP19A1—osteoporosis	8.56e-05	0.000948	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—MTHFR—osteoporosis	8.33e-05	0.000923	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—MTHFR—osteoporosis	8.33e-05	0.000923	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—TNF—osteoporosis	8.3e-05	0.000919	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—IRS1—osteoporosis	8.26e-05	0.000915	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—IRS1—osteoporosis	8.26e-05	0.000915	CbGpPWpGaD
Canagliflozin—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—osteoporosis	8.06e-05	0.000893	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—IL6R—osteoporosis	7.76e-05	0.000859	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—IL6R—osteoporosis	7.76e-05	0.000859	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—OXCT1—osteoporosis	7.74e-05	0.000857	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CA2—osteoporosis	7.74e-05	0.000857	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—ANXA2—osteoporosis	7.71e-05	0.000854	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TLN1—osteoporosis	7.68e-05	0.00085	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—VCL—osteoporosis	7.58e-05	0.000839	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—MGLL—osteoporosis	7.55e-05	0.000835	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—IL1B—osteoporosis	7.4e-05	0.000819	CbGpPWpGaD
Canagliflozin—UGT1A9—NRF2 pathway—TGFB1—osteoporosis	7.32e-05	0.000811	CbGpPWpGaD
Canagliflozin—CYP3A4—Cytochrome P450 - arranged by substrate type—POMC—osteoporosis	7.31e-05	0.000809	CbGpPWpGaD
Canagliflozin—ABCC2—NRF2 pathway—TGFB1—osteoporosis	7.14e-05	0.000791	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	7.12e-05	0.000788	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CYP27A1—osteoporosis	7.09e-05	0.000785	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—IL1B—osteoporosis	7.06e-05	0.000782	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—ADCY5—osteoporosis	7e-05	0.000775	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—GPX1—osteoporosis	6.97e-05	0.000772	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—ANXA2—osteoporosis	6.76e-05	0.000748	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—TNF—osteoporosis	6.76e-05	0.000748	CbGpPWpGaD
Canagliflozin—ALB—Vitamin B12 Metabolism—IL6—osteoporosis	6.7e-05	0.000742	CbGpPWpGaD
Canagliflozin—SLC5A2—Metabolism—POMC—osteoporosis	6.66e-05	0.000738	CbGpPWpGaD
Canagliflozin—SLC5A1—Metabolism—POMC—osteoporosis	6.66e-05	0.000738	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—MTHFR—osteoporosis	6.43e-05	0.000712	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—IDH2—osteoporosis	6.42e-05	0.00071	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—RAP1A—osteoporosis	6.33e-05	0.000701	CbGpPWpGaD
Canagliflozin—ALB—Platelet degranulation—TGFB1—osteoporosis	6.2e-05	0.000687	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CYP27A1—osteoporosis	6.03e-05	0.000668	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—P4HB—osteoporosis	6.03e-05	0.000668	CbGpPWpGaD
Canagliflozin—CYP3A4—Phase 1 - Functionalization of compounds—POMC—osteoporosis	5.93e-05	0.000656	CbGpPWpGaD
Canagliflozin—ALB—Response to elevated platelet cytosolic Ca2+—TGFB1—osteoporosis	5.91e-05	0.000654	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ACP5—osteoporosis	5.87e-05	0.00065	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	5.79e-05	0.000641	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—FGA—osteoporosis	5.74e-05	0.000636	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PKM—osteoporosis	5.5e-05	0.000609	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—FDPS—osteoporosis	5.5e-05	0.000609	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—TGFB1—osteoporosis	5.49e-05	0.000608	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—TPI1—osteoporosis	5.46e-05	0.000604	CbGpPWpGaD
Canagliflozin—ALB—Folate Metabolism—IL6—osteoporosis	5.45e-05	0.000604	CbGpPWpGaD
Canagliflozin—ABCC2—Transmembrane transport of small molecules—ADCY5—osteoporosis	5.39e-05	0.000597	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—TNF—osteoporosis	5.37e-05	0.000594	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—CYP19A1—osteoporosis	5.24e-05	0.00058	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—FGB—osteoporosis	5.22e-05	0.000578	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—osteoporosis	5.22e-05	0.000578	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PGLS—osteoporosis	5.21e-05	0.000577	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GPD2—osteoporosis	5.21e-05	0.000577	CbGpPWpGaD
Canagliflozin—CYP3A4—Metapathway biotransformation—CYP19A1—osteoporosis	5.17e-05	0.000572	CbGpPWpGaD
Canagliflozin—UGT2B4—Metabolism—POMC—osteoporosis	5.15e-05	0.00057	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—P4HB—osteoporosis	5.13e-05	0.000568	CbGpPWpGaD
Canagliflozin—ABCB1—Allograft Rejection—TNF—osteoporosis	5.13e-05	0.000568	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GAPDH—osteoporosis	5.03e-05	0.000557	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—RAP1A—osteoporosis	4.9e-05	0.000543	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PKM—osteoporosis	4.82e-05	0.000533	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—FDPS—osteoporosis	4.82e-05	0.000533	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ATIC—osteoporosis	4.77e-05	0.000528	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PNP—osteoporosis	4.77e-05	0.000528	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—MYC—osteoporosis	4.6e-05	0.000509	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—MYC—osteoporosis	4.6e-05	0.000509	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—IGF1—osteoporosis	4.59e-05	0.000508	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—TGFB1—osteoporosis	4.59e-05	0.000508	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—TGFB1—osteoporosis	4.59e-05	0.000508	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PGLS—osteoporosis	4.57e-05	0.000506	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GPD2—osteoporosis	4.57e-05	0.000506	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—osteoporosis	4.52e-05	0.0005	CbGpPWpGaD
Canagliflozin—ALB—Selenium Micronutrient Network—IL6—osteoporosis	4.33e-05	0.000479	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism of lipids and lipoproteins—POMC—osteoporosis	4.28e-05	0.000473	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PNP—osteoporosis	4.18e-05	0.000463	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ATIC—osteoporosis	4.18e-05	0.000463	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—OXCT1—osteoporosis	4.05e-05	0.000449	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CA2—osteoporosis	4.05e-05	0.000449	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ENO1—osteoporosis	3.96e-05	0.000439	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—MGLL—osteoporosis	3.95e-05	0.000437	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PSMA2—osteoporosis	3.91e-05	0.000432	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—PSMA5—osteoporosis	3.91e-05	0.000432	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—CYP19A1—osteoporosis	3.73e-05	0.000412	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CA2—osteoporosis	3.55e-05	0.000393	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—OXCT1—osteoporosis	3.55e-05	0.000393	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—MGLL—osteoporosis	3.46e-05	0.000383	CbGpPWpGaD
Canagliflozin—SLC5A1—Disease—IL6—osteoporosis	3.46e-05	0.000383	CbGpPWpGaD
Canagliflozin—SLC5A2—Disease—IL6—osteoporosis	3.46e-05	0.000383	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—IDH2—osteoporosis	3.36e-05	0.000372	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—CYP19A1—osteoporosis	3.17e-05	0.000351	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP27A1—osteoporosis	3.16e-05	0.00035	CbGpPWpGaD
Canagliflozin—CYP3A4—Biological oxidations—POMC—osteoporosis	3.15e-05	0.000348	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ACP5—osteoporosis	3.07e-05	0.00034	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—GPX1—osteoporosis	3.03e-05	0.000336	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—FDPS—osteoporosis	2.97e-05	0.000329	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PKM—osteoporosis	2.97e-05	0.000329	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—IDH2—osteoporosis	2.94e-05	0.000326	CbGpPWpGaD
Canagliflozin—ALB—Transmembrane transport of small molecules—ADCY5—osteoporosis	2.89e-05	0.00032	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—TPI1—osteoporosis	2.86e-05	0.000316	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GPD2—osteoporosis	2.81e-05	0.000312	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PGLS—osteoporosis	2.81e-05	0.000312	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP27A1—osteoporosis	2.77e-05	0.000306	CbGpPWpGaD
Canagliflozin—ALB—Platelet activation, signaling and aggregation—TGFB1—osteoporosis	2.75e-05	0.000305	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—osteoporosis	2.72e-05	0.000301	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—osteoporosis	2.71e-05	0.0003	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ACP5—osteoporosis	2.69e-05	0.000298	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—P4HB—osteoporosis	2.69e-05	0.000297	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GAPDH—osteoporosis	2.64e-05	0.000292	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—ADCY5—osteoporosis	2.59e-05	0.000287	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—GPX1—osteoporosis	2.58e-05	0.000286	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ATIC—osteoporosis	2.57e-05	0.000285	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PNP—osteoporosis	2.57e-05	0.000285	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—RAP1A—osteoporosis	2.57e-05	0.000284	CbGpPWpGaD
Canagliflozin—ABCB1—Transmembrane transport of small molecules—ADCY5—osteoporosis	2.54e-05	0.000281	CbGpPWpGaD
Canagliflozin—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—osteoporosis	2.53e-05	0.00028	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—TPI1—osteoporosis	2.5e-05	0.000277	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—MTHFR—osteoporosis	2.38e-05	0.000264	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—IGF1—osteoporosis	2.37e-05	0.000262	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—P4HB—osteoporosis	2.35e-05	0.000261	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GAPDH—osteoporosis	2.31e-05	0.000256	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—RAP1A—osteoporosis	2.25e-05	0.000249	CbGpPWpGaD
Canagliflozin—ALB—Metabolism of lipids and lipoproteins—POMC—osteoporosis	2.24e-05	0.000248	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CA2—osteoporosis	2.19e-05	0.000242	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—OXCT1—osteoporosis	2.19e-05	0.000242	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—MGLL—osteoporosis	2.13e-05	0.000236	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ENO1—osteoporosis	2.08e-05	0.00023	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PSMA2—osteoporosis	2.04e-05	0.000226	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—PSMA5—osteoporosis	2.04e-05	0.000226	CbGpPWpGaD
Canagliflozin—UGT1A9—Metabolism—POMC—osteoporosis	1.9e-05	0.000211	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ENO1—osteoporosis	1.82e-05	0.000201	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—IDH2—osteoporosis	1.81e-05	0.000201	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PSMA2—osteoporosis	1.79e-05	0.000198	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—PSMA5—osteoporosis	1.79e-05	0.000198	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP27A1—osteoporosis	1.7e-05	0.000189	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—CYP19A1—osteoporosis	1.66e-05	0.000184	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ACP5—osteoporosis	1.66e-05	0.000184	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—TPI1—osteoporosis	1.54e-05	0.000171	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—CYP19A1—osteoporosis	1.45e-05	0.000161	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—P4HB—osteoporosis	1.45e-05	0.00016	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GAPDH—osteoporosis	1.42e-05	0.000158	CbGpPWpGaD
Canagliflozin—ALB—Hemostasis—TGFB1—osteoporosis	1.42e-05	0.000157	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—RAP1A—osteoporosis	1.39e-05	0.000153	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—ADCY5—osteoporosis	1.36e-05	0.00015	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—GPX1—osteoporosis	1.35e-05	0.00015	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—MTHFR—osteoporosis	1.25e-05	0.000138	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—ADCY5—osteoporosis	1.19e-05	0.000131	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—GPX1—osteoporosis	1.18e-05	0.000131	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ENO1—osteoporosis	1.12e-05	0.000124	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PSMA5—osteoporosis	1.1e-05	0.000122	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—PSMA2—osteoporosis	1.1e-05	0.000122	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—MTHFR—osteoporosis	1.09e-05	0.000121	CbGpPWpGaD
Canagliflozin—ALB—Metabolism—POMC—osteoporosis	9.97e-06	0.00011	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—CYP19A1—osteoporosis	8.96e-06	9.92e-05	CbGpPWpGaD
Canagliflozin—ABCB1—Metabolism—POMC—osteoporosis	8.74e-06	9.67e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—ADCY5—osteoporosis	7.32e-06	8.1e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—GPX1—osteoporosis	7.29e-06	8.07e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—MTHFR—osteoporosis	6.73e-06	7.45e-05	CbGpPWpGaD
Canagliflozin—CYP3A4—Metabolism—POMC—osteoporosis	5.38e-06	5.96e-05	CbGpPWpGaD
